WALTHAM, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update on corporate activities during the quarter ended March 31, 2016.
“During the first quarter, we announced groundbreaking clinical data for CRLX101 in the Proceedings of the National Academy of Sciences (PNAS), which provides the first proof of mechanism in human cancer patients for our platform technology,” said Christopher D. T. Guiffre, President & Chief Executive Officer of Cerulean.
“During the first quarter, we announced groundbreaking clinical data for CRLX101 in the Proceedings of the National Academy of Sciences (PNAS), which provides the first proof of mechanism in human cancer patients for our platform technology,” said Christopher D. T. Guiffre, President & Chief Executive Officer of Cerulean.
